Rheumatoid arthritis response to treatment across IgG1 allotype - anti-TNF incompatibility: a case-only study.

doi:10.1186/s13075-015-0571-z

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Rheumatoid arthritis response to treatment across IgG1 allotype - anti-TNF incompatibility: a case-only study.

Arthritis research & therapy - 18 Mar 2015

Montes Ariana, Perez-Pampin Eva, Navarro-Sarabia Federico, Moreira Virginia, de la Serna Arturo Rodríguez, Magallares Berta, Vasilopoulos Yiannis, Sarafidou Theologia, Fernández-Nebro Antonio, Ordóñez María Del Carmen, Narváez Javier, Cañete Juan D, Marquez Ana, Pascual-Salcedo Dora, Joven Beatriz, Carreira Patricia, Moreno-Ramos Manuel J, Caliz Rafael, Ferrer Miguel Angel, Garcia-Portales Rosa, Blanco Francisco J, Magro Cesar, Raya Enrique, Valor Lara, Alegre-Sancho Juan J, Balsa Alejandro, Martin Javier, Plant Darren, Isaacs John, Morgan Ann W, Barton Anne, Wilson Anthony G, Gómez-Reino Juan J, Gonzalez Antonio

Abstract excerpt

INTRODUCTION: We have hypothesized that incompatibility between the G1m genotype of the patient and the G1m1 and G1m17 allotypes carried by infliximab (INX) and adalimumab (ADM) could decrease the efficacy of these anti-tumor necrosis factor (anti-TNF) antibodies in the treatment of rheumatoid arthritis (RA). METHODS: The G1m genotypes were analyzed in three collections of patients with RA totaling 1037 subjects....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adalimumab

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antirheumatic Agents

Share to Arthritis, Rheumatoid

Share to Immunoglobulin Allotypes

Share to Immunoglobulin G

Share to Infliximab

Share to Treatment Outcome

Share to Tumor Necrosis Factor-alpha

Source

Open in PubMed Open full text

Identifiers

PMID: 25885039
DOI: 10.1186/s13075-015-0571-z
PMCID: PMC4411723

Genes

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Rheumatoid arthritis response to treatment across IgG1 allotype - anti-TNF incompatibility: a case-only study.PMID 25885039Read ↗

Genetic polymorphisms of FcGR2B and adalimumab effectiveness in Colombian patients with rheumatoid arthritis. Cases-controls studySemantic proximity Read ↗

Fcγ receptor type IIIA polymorphism influences treatment outcomes in patients with rheumatoid arthritis treated with rituximab.Semantic proximity Read ↗

Association between -871C>T promoter polymorphism in the B-cell activating factor gene and the response to rituximab in rheumatoid arthritis patients.Semantic proximity Read ↗

A single tumour necrosis factor haplotype influences the response to adalimumab in rheumatoid arthritis.Semantic proximity Read ↗

Functional FCGR3A 158 V/F and IL-6 -174 C/G polymorphisms predict response to biologic therapy in patients with rheumatoid arthritis: a meta-analysis.Semantic proximity Read ↗

IgG1 heavy chain-coding gene polymorphism (G1m allotypes) and development of antibodies-to-infliximab.Semantic proximity Read ↗

The 158VV Fcgamma receptor 3A genotype is associated with response to rituximab in rheumatoid arthritis: results of an Italian multicentre study.Semantic proximity Read ↗

Association between genetic variants and development of antibodies to infliximab: A cross-sectional study in Chinese patients with Crohn’s diseaseSemantic proximity Read ↗

Influence of FCGR3A-V212F and TNFRSF1B-M196R genotypes in patients with rheumatoid arthritis treated with infliximab therapy.Semantic proximity Read ↗

IgG1 Allotypes Influence the Pharmacokinetics of Therapeutic Monoclonal Antibodies through FcRn Binding.Semantic proximity Read ↗

Treatment- and population-specific genetic risk factors for anti-drug antibodies against interferon-betaSemantic proximity Read ↗

Effectiveness of switching between TNF inhibitors in patients with axial spondyloarthritis: is the reason to switch relevant?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.